Atlas FDA

Orsiro Sirolimus Eluting Coronary Stent System, Orsiro Mission Sirolimus Eluting Coronary Stent System

FDA premarket approval P170030/S022 · decided 2022-08-31

Approval details

PMA number
P170030
Supplement
S022
Supplement type
Normal 180 Day Track No User Fee
Supplement reason
Labeling Change - PAS
Trade name
Orsiro Sirolimus Eluting Coronary Stent System, Orsiro Mission Sirolimus Eluting Coronary Stent System
Generic name
Coronary drug-eluting stent
Applicant
Biotronik AG
Date received
2022-03-04
Decision date
2022-08-31
Days to decision
180 days
Decision code
APPR
Product code
NIQ
Advisory committee
Cardiovascular
Expedited review
No
Location
Bülach
Statement
Approval for the PMA Post-Approval Study Labeling Update for the Orsiro and Orsiro Mission Siolimus Eluting Coronary Stent Systems.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
PHERON PERIPHERAL PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY (PTA) CATHETER (K052757)Biotronik AG2005-10-28